Michelle Cochran
Psychiatry · Nashville, TNNPI 1760587026
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,320 of the $73,579 with a category attached, or 77.9%. Johnson & Johnson accounts for 60.1% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2023 at $28,367 and has fallen 59.2% since, to $11,579 in 2025. Among psychiatry clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 304 payments — averaging $242.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$44K
- Neuronetics, Inc.$25K
- AbbVie$723
- Livanova USA, Inc.$638
- Sunovion Pharmaceuticals Inc.$631
- Alkermes, Inc.$579
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$57,32078%
- Travel & lodging$8,87712%
- Food & beverage$7,38210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 76 | $44,191 |
| Neuronetics, Inc. | 29 | $24,727 |
| AbbVie(2 entities) | 45 | $723 |
| Livanova USA, Inc. | 5 | $638 |
| Sunovion Pharmaceuticals Inc. | 30 | $631 |
| Alkermes, Inc. | 23 | $579 |
| Axsome Therapeutics, Inc. | 18 | $392 |
| Teva Pharmaceuticals USA, Inc. | 7 | $241 |
| Neurocrine Biosciences, Inc. | 9 | $215 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $181 |
| Lundbeck LLC | 7 | $133 |
| Novo Nordisk | 1 | $121 |
| Bausch Health US, LLC | 7 | $119 |
| Vanda Pharmaceuticals Inc. | 6 | $114 |
| E.r. Squibb & Sons, L.L.C. | 4 | $92 |
| Neos Therapeutics, LP | 3 | $52 |
| Alfasigma USA, Inc. | 3 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Adlon Therapeutics L.p. | 1 | $21 |
| Tempus AI, Inc | 1 | $20 |
| Noven Therapeutics, LLC | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$42,958
- NEUROSTAR TMS THERAPY$23,916
- LYBALVI$455
- VNS Therapy Symmetry Model 8103 Generator$265
- VNS - Sentiva$225
- RYBELSUS$121
- VRAYLAR$120
- AUSTEDO$113
- VNS - Symmetry$110
How this compares
$73,579 in reported general payments places this provider in the 95th percentile of 503 psychiatry providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Olanzapine | 11 | $260 |
| Fluoxetine Hcl | 18 | $221 |
| Lamotrigine | 17 | $158 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Nashville
- Rakesh AminNashville$3M
- Robert JamiesonNashville$141K
- Amanda Sparks-BushnellNashville$66K
- Craig ClarkNashville$31K
- Joseph SharpeNashville$29K
- Colleen FriddellNashville$23K
- Jane WeinbergNashville$22K
- Esiri EsinNashville$18K
- Tianlai TangNashville$11K
- Marianne RaynesNashville$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.